All News

What are stem cells, what could they do - and why are investors wary of putting their money in them? A lay guide to the technology

Investing in technology that's a few years from commercialisation can be tricky. Lori Valigra finds out how some venture capitalists sort the wheat from the chaff.

The European Commission's Clinical Trials Directive was meant to make trials more simple. But it looks as if the effect has been to stop many trials taking place at all.

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.

Cambridge University wants rights to the intellectual property generated by its staff. The idea has divided scientists in a university well known for its high-tech spin-outs.

A Swiss team has developed a reliable blood test for younger, live cows. Now it is looking for investment to develop a test for Creutzfeldt-Jakob disease in humans.

On inventive Californians, technology transfer, how to approach the business press, and other insights into R&D management.

"Anything that won't sell, I don't want to invent. Its sale is proof of utility, and utility is success." Thomas A. Edison (1847-1931).

A new Munich-based company that says its patented technologies can reduce household water consumption by 90 per cent on average is looking for more investment.

The UK's National Collection of Yeast Cultures is looking for partners to help it to delve into research on using yeast to contribute to cutting edge science such as fingerprint DNA identification or drug delivery systems

Two New Year's resolutions for the governments around the world that have managed to gum up the economic machinery behind technological development.